Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized amikacin to prevent ventilator-associated pneumonia
IRCT20260601069603N1Phase 3Recruiting
- Sponsor
- Kerman University of Medical Sciences
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of amikacin in ventilator-associated pneumonia (VAP), sponsored by Kerman University of Medical Sciences. Started Jul 2026; status: recruiting.
02
Drugs
amikacin
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on IRCT20260601069603N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260601069603N1.